Cardiovascular Disease

Cardiovascular Disease (CVD) is the leading cause of death in the United States, primarily driven by Coronary Artery Disease (CAD). CAD begins with "Atherogenesis," the formation of fatty plaques in artery linings. Inflammatory cells, oxidized LDL cholesterol, free radicals, and inflammatory proteins accumulate, leading to plaque growth. Delta-Tocotrienols can reduce plaque adhesion. Plaque calcification may cause rupture, forming blood clots that can block arteries, causing heart attacks or strokes.

Delta-Tocotrienols can lower cholesterol levels by up to 20% and reduce tissue inflammation, such as a 40% drop in high-sensitivity C-reactive protein (hsCRP). Clinical trials suggest they inhibit plaque formation and can reverse established plaques. Patients with Severe Carotid Stenosis improved or stabilized with Tocotrienols, while controls worsened. A university study identified 250 mg of Delta-Tocotrienol per day as an effective dose for significant lipid reduction within four weeks. These findings promise improved arterial health, reduced CVD risk, and enhanced blood flow.

References